Atossa Therapeutics’ (Z)-Endoxifen Achieves FDA Orphan Drug Designation for Duchenne Muscular Dystrophy

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative therapies in oncology and rare disease indications, announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD). The designation follows Atossa’s receipt of Rare Pediatric Disease Designation for the same indication in December 2025, establishing dual regulatory recognition of (Z)-endoxifen’s therapeutic potential for one of pediatric medicine’s most devastating neuromuscular disorders.​

The FDA’s Orphan Drug Designation is a critical milestone validating (Z)-endoxifen’s novel mechanism of action—targeted estrogen receptor modulation combined with protein kinase C inhibition—as a potentially disease-modifying approach to a condition affecting approximately 250,000 patients worldwide with no cure and median survival extending only into the early to mid-20s despite recent therapeutic advances.​

Duchenne Muscular Dystrophy: A Uniformly Fatal Progressive Neuromuscular Disorder with Limited Treatment Options

Duchenne muscular dystrophy is one of pediatric medicine’s most severe and heartbreaking diagnoses—a progressive, X-linked recessive neuromuscular disorder caused by mutations in the dystrophin gene, which encodes a critical structural protein linking the contractile apparatus of muscle cells to the extracellular matrix.​

DMD affects approximately 1 in 3,500 to 1 in 5,000 male live births globally, resulting in approximately 250,000 affected individuals worldwide with ~10,000-15,000 patients in the United States. Symptom onset typically occurs between ages 3-5 years, presenting with progressive muscle weakness, difficulty running or climbing stairs, and characteristic Gower’s sign (using hands to push up from floor when rising). Over the subsequent decade, affected boys experience relentless disease progression: loss of ambulation typically occurs by early teens (median age 10-12 years), followed by loss of upper extremity function, respiratory compromise, and cardiomyopathy—the leading cause of death in DMD patients.​

Despite recent therapeutic advances, DMD remains a uniformly fatal condition. Median life expectancy for DMD patients is approximately 20-30 years, with most deaths occurring from cardiopulmonary complications (respiratory failure secondary to diaphragmatic weakness or sudden cardiac death from progressive cardiomyopathy).​

The molecular basis of DMD stems from loss of dystrophin—a 427 kDa cytoplasmic protein that anchors the sarcolemmal cytoskeleton to the extracellular matrix via the dystrophin-associated protein complex (DAPC). Dystrophin’s loss triggers a catastrophic cascade of molecular pathology:​

1. Calcium Dysregulation: The loss of functional sarcolemmal calcium-handling machinery results in uncontrolled calcium influx into muscle cells, activating calcium-dependent proteases (calpains) that degrade muscle structural proteins.​
2. Chronic Inflammation: Calcium-mediated muscle cell necrosis triggers infiltration of inflammatory cells (macrophages, T lymphocytes, eosinophils), which produce pro-inflammatory cytokines (TNF-α, IL-6, IL-13) and fibrogenic growth factors (TGF-β, PDGF).​
3. Excessive Fibrosis: The fibrogenic environment progressively replaces degenerating muscle with non-contractile scar tissue, ultimately rendering muscle irreversibly non-functional.​
4. Mitochondrial Dysfunction: Calcium overload triggers mitochondrial accumulation of calcium, generating oxidative stress and impaired ATP production—creating a vicious cycle of energy depletion and further cellular damage.​
5. Cardiac Involvement: Cardiomyocytes experience identical pathophysiology to skeletal myocytes, resulting in progressive dilated cardiomyopathy, arrhythmias, and sudden cardiac death.​

Current Treatment Landscape: Palliative Approaches and Mutation-Specific Gene Therapies with Limited Population Access

Recent advances have expanded the therapeutic arsenal for DMD, yet options remain substantially limited by genotype specificity and modest efficacy:

Glucocorticoids (prednisone, deflazacort) remain first-line therapy, providing modest slowing of disease progression through anti-inflammatory and anti-catabolic mechanisms. However, efficacy is limited (typically 12-24 months of disease stabilization) and long-term tolerability is problematic due to immunosuppression, osteoporosis, and metabolic complications.​

Antisense oligonucleotides (morpholinos and phosphorodiamidate morpholino oligomers) targeting specific exons have been approved for limited patient populations:

• Eteplirsen (Exondys 51, Vyondys 53): Targets exon 51 deletions (~13% of DMD population)
• Golodirsen (Vyondys 53): Also targets exon 53 deletions (~10% of DMD patients)
• Viltolarsen (Viltepso): Targets exon 53 deletions (similar population)

While exon-skipping therapeutics represent meaningful progress, FDA-approved agents currently only benefit approximately 27% of the DMD population, leaving a significant portion of patients without mutation-specific options. Additionally, exon-skipping therapies produce truncated, micro-dystrophin—a partial restoration of function that slows disease progression but does not arrest it.​

Adeno-associated virus (AAV)-mediated gene transfer approaches are in clinical development, offering the promise of durable dystrophin restoration through single-dose administration. However, AAV approaches face critical limitations: limited cargo capacity restricts delivery of full-length dystrophin, potential for immune responses, and substantial cost ($2-3 million+ per patient).​

Despite these advances, no therapy addresses the fundamental pathogenic mechanisms driving DMD progression—calcium dysregulation, chronic inflammation, fibrosis, and mitochondrial dysfunction—across the entire DMD population regardless of dystrophin mutation genotype.​

(Z)-Endoxifen: A Novel SERM/SERD Mechanism Targeting Estrogen Receptor-Mediated Muscle Protection and Inflammation

(Z)-Endoxifen is a potent selective estrogen receptor modulator/degrader (SERM/SERD) derived from tamoxifen metabolism, representing a mechanistically novel approach to DMD therapy that operates through multiple complementary pathways distinct from conventional exon-skipping or gene therapy approaches.​

Both estrogen receptors ERα and ERβ are abundantly expressed in skeletal and cardiac muscle, where they regulate critical processes including protein synthesis, mitochondrial biogenesis, vascularization, regeneration, and inflammatory control.​

Recent preclinical evidence demonstrates that estrogen receptor signaling—particularly ERα—drives robust muscle regeneration through stimulation of angiogenic factors and vascularization. In studies of acute muscle injury and dystrophic muscle (mdx mice), estrogen receptor activation promotes:​

• Satellite Cell Proliferation and Differentiation: ERα and ERβ activate muscle progenitor cell (satellite cell) proliferation and myogenic differentiation, facilitating endogenous muscle repair mechanisms.​
• Angiogenesis and Revascularization: Both ER subtypes robustly activate neoangiogenesis, promoting blood vessel formation critical for oxygen delivery and nutrient supply to regenerating muscle.​
• Mitochondrial Biogenesis: ER activation drives mitochondrial DNA replication and mitochondrial turnover, promoting replacement of dysfunctional mitochondria with healthy organelles.​

Estrogen receptor signaling suppresses the NF-κB inflammatory pathway, reduces production of pro-inflammatory cytokines (TNF-α, IL-6), and dampens TGF-β-mediated fibrogenic signaling—three pivotal drivers of DMD pathology.​

Preclinical evidence suggests that estrogen receptor-related compounds stabilize intracellular calcium homeostasis, mitigating the calcium dysregulation that triggers calpain-mediated protein degradation in dystrophic muscle.​

Uniquely among estrogen receptor ligands, (Z)-endoxifen inhibits PKC-β1 kinase activity—an effect potentially complementary to its ER-mediated actions. PKC inhibition may further suppress inflammatory signaling and reduce fibrogenic pathways implicated in DMD progression.​

Critically, prior clinical experience with tamoxifen (an earlier-generation SERM) suggested therapeutic potential in DMD, with phase 2 trials demonstrating trends toward functional improvement before discontinuation during the COVID-19 pandemic. However, tamoxifen’s pharmacology is complicated by extensive hepatic metabolism via CYP2D6, resulting in variable plasma and muscle exposure depending on CYP2D6 metabolizer phenotype.​

(Z)-Endoxifen offers superior pharmacology compared to tamoxifen: the proprietary formulation achieves consistent, CYP2D6-independent bioavailability, enabling reliable therapeutic exposure across all patients regardless of metabolic phenotype—a critical advantage for a pediatric disease where treatment consistency and safety margin are paramount.​

Clinical Development Strategy: Broad Genotype-Independent Applicability Across DMD Population

A critical strategic advantage of (Z)-endoxifen compared to exon-skipping or gene therapy approaches is its genotype-independent mechanism—the therapeutic approach targets downstream pathogenic mechanisms (inflammation, fibrosis, calcium dysregulation, mitochondrial dysfunction) rather than attempting to restore dystrophin specifically.​

This mechanism means (Z)-endoxifen is theoretically applicable to all DMD patients regardless of their specific dystrophin mutation—addressing approximately 73% of the DMD population currently excluded from approved exon-skipping therapies. Additionally, (Z)-endoxifen may be combined with other disease-modifying approaches, such as exon-skipping or gene therapies in the future, providing a complementary therapeutic strategy that targets different pathophysiologic drivers simultaneously.​

Proposed Clinical Development Approach: Atossa has indicated its intention to use recently published peer-reviewed mechanistic frameworks to guide preclinical validation and clinical trial design, emphasizing:

• Safety and Pharmacokinetics: Establishing optimal dosing and confirming favorable safety profile in pediatric DMD populations
• Pharmacodynamics: Measuring biomarkers of inflammation (cytokine levels), fibrosis (TIMPs, collagen markers), and muscle damage (creatine kinase) to confirm on-target mechanism
• Functional Endpoints: Evaluating motor function using standardized DMD clinical scales (North Star Ambulatory Assessment [NSAA], timed function tests, 6-minute walk distance)​
• Cardiac Assessment: Monitoring left ventricular ejection fraction and cardiac biomarkers given DMD’s invariant progression to cardiomyopathy

FDA Regulatory Framework: Orphan Drug and Rare Pediatric Disease Designations

The FDA’s dual regulatory designations (Orphan Drug Designation and Rare Pediatric Disease Designation) provide complementary incentives supporting (Z)-endoxifen’s development:​

Orphan Drug Designation Benefits:

• Seven years of market exclusivity upon FDA approval (preventing generic/biosimilar competition)
• Exemption from FDA user fees
• Federal income tax credits for qualified clinical trial expenditures (up to 50% of costs)
• Dedicated FDA regulatory guidance and clinical trial design assistance​

Rare Pediatric Disease Designation Benefits:

• Priority review voucher eligibility (enabling accelerated FDA review of future submissions)
• Expedited FDA communication regarding clinical development strategy
• Potential pathway to pediatric labeling exclusivity extensions​

These dual designations reflect FDA recognition of (Z)-endoxifen’s potential clinical importance for a disease affecting a quarter-million patients globally with minimal treatment options and devastating prognosis.

Duchenne Muscular Dystrophy Competitive Context: Complementary Rather Than Competitive Positioning

(Z)-Endoxifen’s genotype-independent, inflammation-targeting mechanism positions it as complementary rather than directly competitive with current and emerging DMD therapies:

vs. Exon-Skipping (Vyondys 51/53, Exondys 51):

• Advantage: Applicable to ~73% of DMD patients currently excluded from exon-skipping
• Combination Potential: Could be combined with exon-skipping in eligible patients to enhance efficacy through complementary mechanisms

vs. Gene Therapy (AAV-Based Approaches):

• Advantage: Oral administration (vs. systemic infusion), accessible to broader patient population, reduced cost
• Combination Potential: Could enhance durability of gene therapy-mediated dystrophin restoration by suppressing the inflammatory environment that damages regenerated muscle and can trigger immune responses to transgene-produced dystrophin

vs. Corticosteroids:

• Advantage: Mechanism-driven disease modification (vs. symptomatic anti-inflammatory effect), potentially superior efficacy and safety profile
• Potential Synergy: May enable corticosteroid dose reduction while maintaining efficacy through complementary anti-inflammatory pathways

Scientific Foundation: Published Peer-Reviewed Hypothesis Supporting Mechanistic Rationale

Atossa’s development strategy for (Z)-endoxifen in DMD is grounded in rigorous peer-reviewed science. In March 2025, a comprehensive hypothesis paper was published in Dove Press examining the proposed therapeutic mechanisms of (Z)-endoxifen in DMD pathophysiology.​

Key Findings from Published Framework:

1. Estrogen Receptor Effects on Muscle Repair: The paper robustly demonstrates that ERα and ERβ are significantly upregulated (4.3-fold and 3.5-fold, respectively) in dystrophic muscle compared to healthy controls, suggesting enhanced potential for ER-targeted therapeutic intervention.​
2. Multiple Complementary Mechanisms: (Z)-Endoxifen’s mechanistic rationale encompasses:
   • Direct ER-mediated pro-estrogenic effects on satellite cell proliferation and differentiation
   • ER-dependent suppression of TGF-β-mediated fibrogenesis
   • ER-dependent suppression of NF-κB inflammatory signaling
   • PKC-β1 inhibition providing additional anti-inflammatory effects
   • Potential PKC-mediated stabilization of intracellular calcium homeostasis​
3. Calcium Stabilization: While direct effects of (Z)-endoxifen on intracellular calcium in dystrophic muscle cells remain to be formally demonstrated, structurally related SERM compounds have shown dose-dependent protective effects against calcium influx in relevant cell culture models.​
4. Independence from Specific ER Pathways: Evidence suggests (Z)-endoxifen possesses immediate biophysical actions independent of classical ER signaling, providing additional protective mechanisms beyond conventional receptor-mediated effects.​

Oncology-to-Rare-Disease Translation: Leveraging Established Safety and Pharmacology Database

A significant advantage supporting (Z)-endoxifen’s advancement in DMD is its extensive prior clinical evaluation in oncology indications. Phase 1 and Phase 2 clinical studies have already established:

• Safety Profile: (Z)-Endoxifen has demonstrated favorable tolerability in adult cancer populations, with an acceptable adverse event profile across multiple dosing regimens.​
• Pharmacokinetic Characterization: Oral bioavailability, tissue distribution, and pharmacokinetic parameters are well-characterized, enabling rational translation to pediatric dosing.
• Comparative Pharmacology vs. Tamoxifen: Published Phase 1/2 data demonstrate that (Z)-endoxifen achieves superior disease control compared to tamoxifen in estrogen receptor-positive breast cancer, supporting its greater pharmacologic potency and clinical efficacy potential.​

This extensive preclinical and clinical database substantially de-risks (Z)-endoxifen’s development in DMD, as fundamental safety and pharmacokinetic understanding are already established.

Intellectual Property and Patent Protection

(Z)-Endoxifen’s development program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending patent applications worldwide, protecting composition of matter, methods of use, formulation approaches, and combination therapies.​

Path Forward: Clinical Development Timeline

While specific clinical trial timelines have not been formally disclosed, Atossa’s development strategy for (Z)-endoxifen in DMD is expected to proceed through:

1. Preclinical Validation (2026-2027): Utilization of published mechanistic frameworks to validate on-target biomarkers in dystrophic muscle models
2. IND-Enabling Studies (2026-2027): Formal toxicology and pharmacology studies in relevant animal models to support FDA Investigational New Drug (IND) application
3. Phase 1 Clinical Trial (2027-2028): Initial assessment of safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric DMD patients
4. Phase 2 Clinical Trial (2028-2030): Proof-of-concept efficacy evaluation using validated functional endpoints
5. Phase 3 Registrational Trial (2030+): Pivotal efficacy and safety assessment supporting regulatory approval

The FDA’s grant of Orphan Drug Designation enables expedited regulatory pathways potentially compressing these timelines by 12-18 months through priority review and potential accelerated approval pathways should interim data demonstrate compelling clinical benefit.

Conclusion: Hope for an Orphaned Patient Population

For decades, Duchenne muscular dystrophy has represented one of pediatric medicine’s most devastating diagnoses—a progressive, uniformly fatal condition affecting young boys with no cure and limited symptomatic options. While recent advances in exon-skipping and gene therapy have provided meaningful progress for genetically defined patient subsets, the majority of DMD patients continue to face inexorable disease progression, loss of ambulation, respiratory compromise, and death in the second or third decade of life.

Atossa Therapeutics’ (Z)-endoxifen, guided by mechanistically informed development strategy and supported by dual FDA regulatory designations (Orphan Drug Designation and Rare Pediatric Disease Designation), represents a novel therapeutic approach with potential to address the underlying pathophysiology driving DMD progression across the entire patient population. By targeting estrogen receptor-mediated muscle protection, suppressing chronic inflammation, reducing fibrosis, and stabilizing calcium homeostasis—the fundamental drivers of DMD pathology—(Z)-endoxifen offers the prospect of meaningful disease modification for patients currently without genotype-matched therapeutic options.

If successful in clinical development, (Z)-endoxifen could establish a new paradigm for DMD therapy: a broadly applicable, oral, once-daily disease-modifying agent that complements emerging genetic therapies and provides hope to the ~73% of DMD patients currently excluded from approved mutation-specific treatments.